Trial Profile

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alpelisib (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

01 Mar 2019 Results published in the Cancer Science
12 Sep 2017 Results assessing food effect on pharmacokinetics of alpelisib and prliminary effecacy (n=33) presented at the 42nd European Society for Medical Oncology Congress
26 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com